<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30459650</article-id>
<article-id pub-id-type="pmc">6232167</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2018.00544</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Astrocytic Regulation of Glutamate Transmission in Schizophrenia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mei</surname>
<given-names>Yu-Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/615265/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Dong Chuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/473885/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Ning</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/520866/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Translational Medicine Research Center, China Medical University Hospital</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff>
<aff id="aff2"><sup>2</sup><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Kenji Hashimoto, Chiba University, Japan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jennifer C. Felger, Emory University, United States; Kurt Leroy Hoffman, Autonomous University of Tlaxcala, Mexico</p>
</fn>
<corresp id="c001">*Correspondence: Ning Zhou <email>ningzhou.nrsc@gmail.com</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>544</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Mei, Wu and Zhou.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Mei, Wu and Zhou</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>According to the glutamate hypothesis of schizophrenia, the abnormality of glutamate transmission induced by hypofunction of NMDA receptors (NMDARs) is causally associated with the positive and negative symptoms of schizophrenia. However, the underlying mechanisms responsible for the changes in glutamate transmission in schizophrenia are not fully understood. Astrocytes, the major regulatory glia in the brain, modulate not only glutamate metabolism but also glutamate transmission. Here we review the recent progress in understanding the role of astrocytes in schizophrenia. We focus on the astrocytic mechanisms of (i) glutamate synthesis via the glutamate-glutamine cycle, (ii) glutamate clearance by excitatory amino acid transporters (EAATs), (iii) D-serine release to activate NMDARs, and (iv) glutamatergic target engagement biomarkers. Abnormality in these processes is highly correlated with schizophrenia phenotypes. These findings will shed light upon further investigation of pathogenesis as well as improvement of biomarkers and therapies for schizophrenia.</p>
</abstract>
<kwd-group>
<kwd>schizophrenia</kwd>
<kwd>glutamate</kwd>
<kwd>NMDA receptors</kwd>
<kwd>excitatory amino acid transporters</kwd>
<kwd>glutamate-glutamine cycle</kwd>
<kwd>D-serine</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="113"></ref-count>
<page-count count="10"></page-count>
<word-count count="7615"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Dysregulation of glutamatergic neurotransmission is critically implicated in the pathophysiology of psychotic disorders. In the central nervous system (CNS), glutamate is the principal excitatory neurotransmitter and mediates the fast excitatory transmission by activation of ionotropic glutamate receptors, including AMPA, kainate, and NMDA receptors (NMDARs). Astrocytes affect glutamatergic transmission in several important ways, including glutamate biosynthesis, glutamate-glutamine cycle, glutamate uptake, and releasing glutamate and D-serine as gliotransmitters. This review focuses on recent advances in astrocyte-mediated dysregulation of glutamate transmission in schizophrenia.</p>
</sec>
<sec id="s2">
<title>The glutamate hypothesis of schizophrenia</title>
<p>The “glutamate hypothesis of schizophrenia” proposes that schizophrenia symptoms and cognitive impairment are due to hypofunction of NMDARs and excessive glutamate release, especially in brain areas including prefrontal cortex and hippocampus (<xref ref-type="bibr" rid="B1">1</xref>). This theory was initiated from the observation that NMDAR antagonists, like phencyclidine and ketamine, could evoke negative symptoms and cognitive dysfunction resembling schizophrenic phenotypes in healthy subjects (<xref ref-type="bibr" rid="B2">2</xref>). In schizophrenic subjects, subanesthetic doses of ketamine could exacerbate psychotic and cognitive symptoms (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Interestingly, in encephalitis patients, the first-episode psychosis is associated with the presence of anti-NMDAR antibodies that could cause a reduction of surface expression of NMDARs (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). In animal studies, suppression of NMDAR function by pharmacological or genetic approaches leads to schizophrenia-like behaviors (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Schizophrenia is also associated with dysregulation of some genes and/or proteins involved in glutamate transmission (<xref ref-type="bibr" rid="B9">9</xref>). Genome-wide association studies have reported that the NMDAR subunits encoding genes, GRIN2A and GRIN2B, are schizophrenia-related genes (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Two <italic>de novo</italic> mutations in GRIN2A were found in sporadic schizophrenia patients (<xref ref-type="bibr" rid="B11">11</xref>). The single nucleotide polymorphisms of genes related to D-serine synthesis and metabolism, such as genes encoding serine racemase (SR), D-Amino Acid Oxidase (DAAO), and the DAAO activator G72, are also associated with schizophrenia (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>The hypofunction of NMDAR causes excessive glutamate release, hyper-glutamatergic functions, and hypermetabolism (<xref ref-type="bibr" rid="B13">13</xref>). However, it remains largely unknown how NMDAR hypofunction leads to elevated glutamate levels and over-activation of non-NMDA glutamate receptors. One possibility is that interneurons are more sensitive to NMDAR blockade than principal glutamatergic neurons, and interneuron inhibition leads to an overall effect of disinhibition and hyperexcitation of glutamatergic output (Figure <xref ref-type="fig" rid="F1">1</xref>) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The increased glutamate levels have been documented by brain imaging studies and the source of excessive glutamate is mainly from presynaptic release (<xref ref-type="bibr" rid="B16">16</xref>). This notion was strengthened by the effect of drugs that specifically reduce presynaptic glutamate release, like the mGluR2/3 agonists, which significantly reverse ketamine-evoked glutamate elevation and cerebral blood volume increase in the hippocampus (<xref ref-type="bibr" rid="B13">13</xref>). High extracellular glutamate levels lead to hypermetabolism, structural disorganization, and eventually hippocampal volume reduction, and these dysfunctions are correlated with disease progression from prodromal symptoms to psychosis (<xref ref-type="bibr" rid="B17">17</xref>). Nevertheless, many mechanisms that cause an overall increase in glutamate tone could contribute synergistically to schizophrenia pathogenesis.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>The NMDAR hypofunction hypothesis proposes that NMDARs in inhibitory interneurons are preferentially diminished in schizophrenia. The reduced NMDAR function in interneurons (the left inset) results in decreased excitatory postsynaptic currents, which in turn decrease interneuron output (the right inset). The reduced GABA release from interneuron terminals leads to smaller inhibitory postsynaptic responses and thereby a disinhibition of postsynaptic excitatory neurons (the right inset). This finally leads to an enhanced output of excitatory neurons, resulting in excessive glutamate release and increased activation of non-NMDA glutamate receptors. This process might be enhanced by NMDAR antagonists and ameliorated by mGluR2/3 agonists.</p>
</caption>
<graphic xlink:href="fpsyt-09-00544-g0001"></graphic>
</fig>
</sec>
<sec id="s3">
<title>Synaptic and extrasynaptic NMDARs</title>
<p>NMDARs are distributed at both synaptic and extrasynaptic sites with different subunit compositions. Their activation requires the binding of both glutamate and D-serine/glycine as a co-agonist. Synaptic NMDARs are activated by presynaptic glutamate release at low frequency, while intensive synaptic activation could lead to glutamate spillover and activation of extrasynaptic NMDARs (<xref ref-type="bibr" rid="B18">18</xref>). Synaptic NMDARs are important for synaptic plasticity and learning and memory, which is largely controlled by D-serine concentration within the synaptic cleft depending on astrocyte coverage and function (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Moreover, extrasynaptic NMDARs are in close proximity to synapse-enveloping astrocytes and are a preferential target for astrocyte-released glutamate, D-serine, and glycine (Figure <xref ref-type="fig" rid="F2">2</xref>). Activation of extrasynaptic NMDARs could generate two forms of responses. First, ambient glutamate could produce a tonic NMDAR current, whose amplitude is directly modulated by glial EAATs (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). The tonic NMDAR currents contribute to neuronal excitability and their existence has been identified in multiple neuron types in the prefrontal cortex, hippocampus, and cerebellum (<xref ref-type="bibr" rid="B23">23</xref>–<xref ref-type="bibr" rid="B25">25</xref>). Second, activation of extrasynaptic NMDARs could produce “slow inward currents” (SICs), which are infrequent phasic events characterized by slow activation and decay kinetics, large amplitude, and insensitivity to sodium channel blockers. It is believed that SICs are due to astrocyte-originated glutamate and the co-occurrence of SICs in adjacent neurons could lead to synchronized neuronal activity (<xref ref-type="bibr" rid="B26">26</xref>). It is also possible that SICs are generated by the phasic release of D-serine/glycine, which potentiates extrasynaptic NMDARs that are already tonically activated by low concentrations of ambient glutamate (<xref ref-type="bibr" rid="B18">18</xref>). While accumulating evidence has demonstrated a critical role of deficient synaptic NMDARs in schizophrenia (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>), alterations in the expression and function of extrasynaptic NMDARs are less understood. It was recently reported that the tonic NMDAR conductance was significantly larger and more sensitive to NMDAR blockers in interneurons compared with pyramidal neurons in the hippocampus (<xref ref-type="bibr" rid="B29">29</xref>). However, it remains to be determined whether extrasynaptic NMDAR deficiency occurs under schizophrenic conditions.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic depiction of the astrocyte-related mechanisms in the metabolism, transport, uptake of glutamate and the regulation of glutamate transmission. Glutamate is synthesized <italic>de novo</italic> from α-KG via the TCA cycle (1). In the glutamate-glutamine cycle (2–4), glutamate is metabolized to glutamine by GS in the astrocyte and then transported to the neuron (2). Neuronal PAG catalyzes the conversion from glutamine into glutamate, which is released as the transmitter from presynaptic terminal (3). The synaptically released glutamate is rapidly uptake by EAATs back into the astrocytes (4). Glutamate can be released as a gliotransmitters by either Ca<sup>2+</sup>-dependent vesicular release (5) or efflux from transporters or large-conductance ion channels (6). D-serine is converted from L-serine, which is synthesized <italic>de novo</italic> from 3-phosphoglycerate in astrocytes (7). D-serine can be released via either vesicular or non-vesicular mechanisms and activate neuronal NMDA receptors (8). Glycine is transported across astrocytic membrane via glycine receptors (9). 3PG, 3-phosphoglycerate; α-KG, α-ketoglutarate; Glu, glutamate; Gln, glutamine; GS, glutamine synthetase; L-Ser, L-serine; D-Ser, D-serine; PAG, phosphate-activated glutaminase; SR, serine racemase; ASCT, alanine-serine-cysteine transporter; xCT, cystine-glutamate antiporter; GLAST, glutamate aspartate transporter; GLT-1, glutamate transporter 1; GlyT-1, glycine transporter 1; mGluR, metabotropic glutamate receptor; IP3R, inositol trisphosphate receptor.</p>
</caption>
<graphic xlink:href="fpsyt-09-00544-g0002"></graphic>
</fig>
</sec>
<sec id="s4">
<title>Astrocytes and glutamate transmission</title>
<p>Regulation of glutamate transmission could occur at several steps, including synthesis, transportation, release, and clearance of glutamate, as well as activation of glutamate receptors by endogenous agonists and co-agonists. Figure <xref ref-type="fig" rid="F2">2</xref> summarizes some key mechanisms underlying the impact of astrocytes in glutamate transmission in the CNS. Astrocytes are the primary locus for the biosynthesis of glutamate from glucose. Through the tricarboxylic acid cycle, the glycolysis product pyruvate is converted into α-ketoglutarate, which is then catalyzed into glutamate by aspartate aminotransferase (<xref ref-type="bibr" rid="B30">30</xref>). Glutamate is catalyzed by glutamine synthetase (GS), which is exclusively expressed in astrocytes in the brain, to form glutamine that is further transferred to neurons. In glutamatergic neurons, glutamate is converted from glutamine by phosphate-activated glutaminase (<xref ref-type="bibr" rid="B30">30</xref>). After packaged into synaptic vesicles, glutamate is released as the neurotransmitter to active postsynaptic AMPA/kainate receptors to mediate fast excitatory synaptic transmission, and to activate NMDARs to depolarize the postsynaptic membrane potential and to allow Ca<sup>2+</sup> influx. The clearance of excessive glutamate from the synaptic cleft occurs rapidly, largely due to the function of four subtypes of EAATs (EAAT1-4), among which the EAAT1 (also termed glutamate-aspartate transporter, GLAST) and EAAT2 (also termed glutamate transporter 1, GLT-1) are mainly expressed in astrocytes (<xref ref-type="bibr" rid="B31">31</xref>). Once glutamate is taken up into astrocytes, it is converted into glutamine and re-enters the glutamate-glutamine cycle. Besides their key roles in the biosynthesis of glutamate and maintenance of the glutamate-glutamine cycle, astrocytes can directly release glutamate as a gliotransmitters by either Ca<sup>2+</sup>-dependent vesicular exocytosis or by non-vesicular release (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Astrocytes are also a major source of glycine and D-serine to potentiate NMDAR responses. Glycine is stored in astrocytes with high concentrations (3–6 mM) and can be released via the reversed operation of glycine transporters and other Ca<sup>2+</sup>-independent pathways (<xref ref-type="bibr" rid="B34">34</xref>–<xref ref-type="bibr" rid="B36">36</xref>). The synthesis of D-serine is initiated from the glycolytic intermediate metabolite 3-phosphoglycerate, which is synthesized into L-serine in several steps. D-serine is converted from L-serine by the action of SR and is released by Ca<sup>2+</sup>-dependent and/or -independent machineries from astrocytes (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B37">37</xref>) [but see (<xref ref-type="bibr" rid="B38">38</xref>)]. Notably, these above processes might interact with one another; for example, the increased glutamate synthesis leads to elevated glutamate release (<xref ref-type="bibr" rid="B39">39</xref>), and activation of glutamate transports could evoke rapid glutamine release as a feedback mechanism (<xref ref-type="bibr" rid="B40">40</xref>).</p>
</sec>
<sec id="s5">
<title>EAATs</title>
<p>The efficiency of glutamate clearance directly affects extracellular resting glutamate levels and kinetics of glutamate-mediated synaptic responses. Among the total four subtypes of brain-expressed EAATs, EAAT1, and EAAT2 are mainly expressed in astrocytes, and EAAT2 is the dominant transporter in adults and is responsible for about 90% of total glutamate uptake (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). The EAATs are mainly responsible for clearing synaptic glutamate and shaping postsynaptic responses. Deficits in EAAT functions cause the persistently increased glutamate levels, which represent one of the most remarkable changes in the schizophrenic brain. Accumulating evidence has reported abnormal mRNA and/or protein expression levels of EAATs in the prefrontal cortex, hippocampus, and anterior cingulate cortex in the postmortem tissue from schizophrenia patients. While many studies have revealed an overall reduction of EAAT2 levels in schizophrenia, some other studies reported unchanged or increased EAAT2 levels in certain brain regions [for review see (<xref ref-type="bibr" rid="B43">43</xref>)]. In a recent study using the laser-capture microdissection technique to separately harvest glutamatergic relay neurons and astrocytes from the mediodorsal nucleus of thalamus, it was reported that changes of EAAT levels could be cell-specific: mRNA expression of EAAT1 was decreased in astrocytes, whereas EAAT2 was increased in excitatory relay neurons in schizophrenia (<xref ref-type="bibr" rid="B44">44</xref>). The upregulation of EAATs in neurons is possibly due to a compensatory response to the reduced EAAT levels in astrocytes. Notably, the mRNA levels of EAAT2b were remarkably increased in anterior cingulate cortex pyramidal neurons and thalamus relay neurons in schizophrenia (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). EAAT2b is a splicing variant of EAAT2. It contains the PDZ domain-binding motif and possibly interacts with neuronal scaffolding proteins like PSD-95 (<xref ref-type="bibr" rid="B45">45</xref>–<xref ref-type="bibr" rid="B47">47</xref>). The EAAT2b proteins are localized predominantly at the cell surface and their distribution can be regulated by intracellular Ca<sup>2+</sup> and CaMKII (<xref ref-type="bibr" rid="B48">48</xref>), suggesting that EAAT2b might exhibit neuronal specific functions.</p>
<p>The abnormal EAAT levels are highly associated with schizophrenia phenotypes. Mice lacking EAAT1 displayed schizophrenia-like behavioral changes: they showed higher locomotor activity in the novel environment but not in the home cage, and had increased sensitivity to the locomotor hyperactivity induced by NMDA antagonists (<xref ref-type="bibr" rid="B49">49</xref>). The locomotor hyperactivity of EAAT1 knockout mice was reversed by either the antipsychotic haloperidol or the mGlu2/3 agonist LY379268 (<xref ref-type="bibr" rid="B49">49</xref>). These mice also exhibited abnormalities in behavioral tests that measure the negative and cognitive symptoms of schizophrenia, including poor nesting behaviors, lesser preference for novel social stimulus albeit normal overall social interaction, a significant reduction in acoustic startle amplitude, and impaired learning in an instrumental visual discrimination task, suggesting that EAAT1 dysfunction could generate certain behavioral changes resembling schizophrenia phenotypes (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>). Knockout of EAAT2 caused lethal spontaneous seizures, high susceptibility to brain injury, and short life-span in the homozygous mice (<xref ref-type="bibr" rid="B51">51</xref>). The heterozygous EAAT2 knockout mice had less severe abnormalities, and they exhibited increased locomotion activity in a new environment and greater freezing responses in the fear-conditioning test compared to the wildtype (<xref ref-type="bibr" rid="B52">52</xref>). The EAAT1/2 double knockout mice showed multiple brain defects resembling developmental defects found in schizophrenia (<xref ref-type="bibr" rid="B53">53</xref>). In a recent study, the inducible EAAT2 knockout mice were generated in a temporal controlled, cell-specific manner. The study demonstrated that knockout during adolescence caused 60–80% reduction of EAAT2 selectively in astrocytes, and the animals showed no lethal seizures or neuronal loss. Interestingly, these animals exhibited pathological repetitive behaviors, like excessive self-grooming and tic-like head shakes, whereas they had no obvious anxiety or social abnormality (<xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>It remains unknown how EAAT abnormality leads to schizophrenia-relevant behaviors. In hippocampus, pharmacological inhibition of EAAT functions increased the peak amplitude of NMDAR-mediated EPSCs and prolonged their decay kinetics, but had no changes in AMPA receptor-mediated EPSCs, possibly due to the fast desensitization of AMPA receptor currents (<xref ref-type="bibr" rid="B55">55</xref>). It has been generally considered that EAATs could limit glutamate spillover to neighboring synapses and enhance synapse independence, which is related to synaptic plasticity as well as learning and memory (<xref ref-type="bibr" rid="B31">31</xref>). Reduced expression of glial EAATs will not only impair these important physiological functions but also increase the susceptibility of the brain to injury and cell death (<xref ref-type="bibr" rid="B51">51</xref>). Neuronal EAATs might have much lower efficiency than the astrocytic transports: glutamate is quickly converted into glutamine by GS, resulting in low free glutamate concentrations in astrocytes; whereas neurons are liable to accumulate intracellular glutamate concentration and thereby lead to poor operation of neuronal EAATs. Moreover, the action of EAATs will produce a non-stoichiometrically coupled anion current (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>), which contributes to the regulation of neuronal membrane potentials and transmitter release (<xref ref-type="bibr" rid="B58">58</xref>). In the zebrafish photoreceptor synapse, the EAAT2b isoform mediates a large-conductance Cl<sup>−</sup> current, potentially capable of affecting resting membrane potentials (<xref ref-type="bibr" rid="B59">59</xref>). Nevertheless, these mechanisms remain to be determined in schizophrenia and may vary depending on the brain region and disease progression.</p>
</sec>
<sec id="s6">
<title>The glutamate-glutamine cycle</title>
<p>Schizophrenia is associated with the abnormal glutamate-glutamine cycle. Altered levels of brain metabolites including glutamate, GABA, and glutamine have been well-documented in human studies and these alterations can be detected in different brain regions and the cerebrospinal fluid (CSF) (<xref ref-type="bibr" rid="B60">60</xref>). Researchers using proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) have reported abnormal glutamine and/or glutamate levels (some studies report glutamate+glutamine levels in combination depending on the <sup>1</sup>H-MRS approach and field strength), especially in the brain regions involving the medial temporal lobe (including hippocampus), basal ganglia, and thalamus of schizophrenia patients (<xref ref-type="bibr" rid="B61">61</xref>). An elevation of the glutamate+glutamine level was also observed in hippocampus of healthy humans receiving ketamine administration (<xref ref-type="bibr" rid="B62">62</xref>). The CSF glutamine/glutamate ratio is higher in the first-episode patients compared with normal controls (<xref ref-type="bibr" rid="B63">63</xref>). GS, the key enzyme involved in the glutamate-glutamine cycle, exhibits lower protein levels in spite of increased expression of mRNA in schizophrenia; but the results were less consistent among studies [for review see (<xref ref-type="bibr" rid="B43">43</xref>)]. Elevated glutamine levels are also directly related to psychotic symptoms and neuropsychological tests (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Although changed glutamine levels are supposedly related to functional alterations of astrocytes, it is notable that the <sup>1</sup>H-MRS and CSF data cannot provide a precise measure of intracellular vs. extracellular substrates and further evidence is needed to establish the causality.</p>
<p>Disturbance of the glutamate-glutamine cycle and down-regulation of GS have also been reported in human epilepsy (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>). Reduced GS activity will build up intracellular glutamate in astrocytes, leading to reduced uptake capacities of EAATs. Moreover, glutamine produced by astrocytic GS is also one of the major sources for maintaining synaptic vesicle content of GABA in inhibitory interneurons (<xref ref-type="bibr" rid="B68">68</xref>). Pharmacological inhibition of GS reduced inhibitory postsynaptic currents in hippocampal pyramidal neurons and was reversed by exogenous application of glutamine (<xref ref-type="bibr" rid="B68">68</xref>). Similar dysfunction of the inhibitory synaptic response was also found in neurons near reactive astrocytes, which showed profound decreases in GS expression levels (<xref ref-type="bibr" rid="B69">69</xref>). These effects increased network hyperexcitability and produced spontaneous recurrent seizures (<xref ref-type="bibr" rid="B70">70</xref>). The loss of interneurons and deficient cortical GABA synthesis are also one of the most robust pathologies of schizophrenia (<xref ref-type="bibr" rid="B71">71</xref>–<xref ref-type="bibr" rid="B73">73</xref>). The reduced parvalbumin interneurons are associated with impaired oscillatory activity in hippocampus and imbalance of cortical excitation-inhibition (<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B74">74</xref>). Impaired parvalbumin interneuron activity by selective deletion of ErbB4 or dopamine D2 receptors produced schizophrenia-like behaviors in mice (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>). Dysfunction of neuron-astrocyte interaction has been suggested in schizophrenia models (<xref ref-type="bibr" rid="B77">77</xref>). However, it remains unclear whether there is any causative relationship between the dysfunction of the glutamate-glutamine cycle and interneuron deficiency.</p>
</sec>
<sec id="s7">
<title>D-serine</title>
<p>D-serine plays an important role in the dysregulation of NMDAR functions in schizophrenia (<xref ref-type="bibr" rid="B78">78</xref>). This was supported by several lines of evidence, including the reduced serum and CSF D-serine levels (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>), a genetic association of SR and DAAO (the enzyme responsible for the degradation of D-serine) polymorphisms in schizophrenia patients (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B81">81</xref>), the reversal effects of D-serine on schizophrenia-like behaviors in animals (<xref ref-type="bibr" rid="B82">82</xref>), and the beneficial effects of clinical D-serine-targeting therapies in patients (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>).</p>
<p>Recent studies revealed that the abnormality in astrocyte-released D-serine plays a critical role in the DISC1-associated pathological processes. The DISC1 gene was identified from patients with familial mental disorders and has been considered a critical susceptibility gene for schizophrenia (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). The density of DISC1-expressing astrocytes is largely reduced in the dentate gyrus of hippocampus in schizophrenia patients compared with healthy controls (<xref ref-type="bibr" rid="B87">87</xref>). Selective expression of mutant DISC1 in astrocytes decreased protein levels of SR by increasing its ubiquitination (<xref ref-type="bibr" rid="B88">88</xref>). Astrocytes expressing mutant DISC1 caused less elaborated dendritic arborization and decreased the density of excitatory synapses in co-cultured normal neurons (<xref ref-type="bibr" rid="B89">89</xref>). The downregulation of SR resulted in a significant decline in D-serine levels, an enhanced locomotor activity, and impaired responses to pre-pulse inhibition in the mutant mice (<xref ref-type="bibr" rid="B88">88</xref>). Mice carrying the astrocytic specific mutation of DISC1 also exhibited increased anxiety, attenuated social interaction and preference for social novelty, and impaired cognitive behaviors (<xref ref-type="bibr" rid="B90">90</xref>). These behavioral abnormalities in DISC1 mutant mice were reversed by treatments of D-serine (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B90">90</xref>), indicating a strong correlation with NMDAR hypofunction.</p>
<p>The α7 subunit-containing nicotinic acetylcholine receptor (α7 nAChR) has been considered a strong genetic contribution to schizophrenia (<xref ref-type="bibr" rid="B91">91</xref>). It has been reported that activation of α7 nAChR contributes to dopamine release and induction of long-term potentiation (<xref ref-type="bibr" rid="B91">91</xref>). Interestingly, α7 nAChRs are expressed not only in neurons but also in astrocytes (<xref ref-type="bibr" rid="B92">92</xref>–<xref ref-type="bibr" rid="B94">94</xref>). ACh could induce the intracellular Ca<sup>2+</sup> elevation in astrocytes by activation of α7 nAChRs and facilitate the synthesis and release of D-serine (<xref ref-type="bibr" rid="B94">94</xref>–<xref ref-type="bibr" rid="B97">97</xref>). Papouin et al. recently discovered that astrocytic α7 nAChRs activation could drive the vesicular release of D-serine from astrocytes to generate a wakefulness-dependent D-serine oscillation <italic>in z</italic> (<xref ref-type="bibr" rid="B98">98</xref>). The wakefulness and activity but not the circadian rhythms of the animal promote D-serine fluctuations over the 24 h period, during which D-serine was accumulated during the wakefulness and declined during sleep. Such an oscillation of the D-serine level is associated with NMDAR activity and the learning and memory behavior of the animal, consistent with the involvement of NMDARs in the cognitive deficits in schizophrenia. Astrocytes appear to play a central role since D-serine accumulation during the wakefulness is impaired by disruption of astrocytic vesicular exocytosis machinery or by selective deletion of α7 nAChRs from astrocytes rather than neurons. More importantly, EVP-6124, an α7 nAChR modulator tested in schizophrenia clinical trials, is able to promote D-serine release and enhance NMDAR activity (<xref ref-type="bibr" rid="B98">98</xref>).</p>
</sec>
<sec id="s8">
<title>Potential biomarkers</title>
<p>Several types of translational biomarkers have been developed to assess prognosis and monitor disease progression and treatment in schizophrenia. First, functional magnetic imaging (fMRI) blood-oxygenation-level dependent response (BOLD) has been applied to test brain physiology following acute NMDAR antagonist administration. NMDAR antagonists evoke robust changes in relative cerebral blood volume and local metabolism, which is largely due to the energy consumption for increased glutamate release and uptake (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B99">99</xref>). The second approach applies <sup>1</sup>H-MRS to measure glutamine and/or glutamate levels in the brain (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B100">100</xref>). As described above, abnormal glutamine and/or glutamate indices were found in brain regions of individuals with schizophrenia compared with healthy volunteers (<xref ref-type="bibr" rid="B61">61</xref>). The third method utilizes task-based fMRI to evaluate BOLD responses in hippocampus and dorsolateral prefrontal cortex (<xref ref-type="bibr" rid="B101">101</xref>). The most adapted task is item-specific encoding task, which is designed to assess contributions of specific encoding and retrieval processes to episodic memory (<xref ref-type="bibr" rid="B102">102</xref>). Schizophrenia patients with more severe negative symptoms exhibited poor BOLD responses during the encoding and retrieval of episodic memory (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B103">103</xref>). And fourth, positron emission tomography (PET) technique has been used to evaluate glutamatergic, GABAergic, and monoamine neurotransmission in various brain functions and have established the association between these responses and cognitive functions in schizophrenia (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>). Finally, the severity of schizophrenia symptoms is associated with abnormal serum levels of several glutamate transmission related factors, including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), D-serine, G72, and multiple inflammatory factors (<xref ref-type="bibr" rid="B106">106</xref>–<xref ref-type="bibr" rid="B108">108</xref>). A recent clinical study by Javitt et al. compared the first three types of glutamatergic target-engagement biomarkers in healthy volunteers receiving ketamine or placebo infusions (<xref ref-type="bibr" rid="B109">109</xref>). The data revealed a significant increase in the NMDAR antagonist-evoked BOLD responses. The <sup>1</sup>H-MRS results showed a smaller but significant change in glutamate+glutamine levels. However, the data from task-based fMRI failed to yield a significant difference between the ketamine and placebo group (<xref ref-type="bibr" rid="B109">109</xref>). These observations indicate the fMRI BOLD as a particularly relevant biomarker for NMDAR antagonist-induced responses. The potential application of one or combined biomarkers for more refined prognostic classification of schizophrenia remains to be further assessed.</p>
</sec>
<sec id="s9">
<title>Future treatments</title>
<p>Based on the glutamate hypothesis, many drug targets have been proposed and some are under investigation. For example, drugs targeting the co-agonist binding site of NMDARs are of the primary interest [for review see (<xref ref-type="bibr" rid="B110">110</xref>)]. Direct enhancement of NMDAR functions with glycine and D-serine has been used in multiple clinical trials, among which one recent study showed improved negative symptoms in individuals at clinical high risk of schizophrenia (<xref ref-type="bibr" rid="B111">111</xref>). GlyT1 inhibitors, like sarcosine or Bitopertin, which are supposed to increase synaptic glycine levels, have been found effective in several trials (<xref ref-type="bibr" rid="B112">112</xref>). Other treatments to increase D-serine/glycine levels, like the DAAO inhibitor sodium benzoate, have demonstrated beneficial effects as an add-on drug (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). The mGluR2/3 agonists have been shown to inhibit excessive glutamate release in animal studies, and the tested drug LY2140023 has produced significant improvement in patients (<xref ref-type="bibr" rid="B113">113</xref>). Moreover, the α7 nAChR has attracted much attention; several drugs targeting this receptor are under clinical investigation (<xref ref-type="bibr" rid="B110">110</xref>). Besides these, more specific regulation of certain proteins in the glutamate transmission, such as selective NMDAR subtypes or EAAT isoforms, might represent potential targets for future drug development.</p>
</sec>
<sec id="s10" sec-type="conclusions">
<title>Conclusions</title>
<p>The glutamate hypothesis has substantially advanced our understanding of the pathogenesis of schizophrenia. Although glutamate transmission is mediated by ionotropic glutamate receptors and involves other pre- and post-synaptic components at excitatory synapses, astrocytes regulate glutamate metabolism and shape glutamate transmission in several important aspects. This review has focused on some recent studies that explicitly report the important role of glutamate uptake, glutamate-glutamine cycle, and astrocyte-derived D-serine in the etiology of schizophrenia. Neuroimaging and neurochemical biomarkers based on glutamate transmission and metabolism have also demonstrated translational utility. Further understanding of neuron-astrocyte interaction during these processes will be critical to the development of diagnostic and therapeutic avenues for schizophrenia and psychotic disorders.</p>
</sec>
<sec id="s11">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>This study was supported by grants to NZ and DW from the Ministry of Science and Technology (MOST 107-2320-B-039-060-MY3 and MOST 107-2320-B-039-061-MY3) and China Medical University Hospital (DMR-106-113).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>B</given-names></name><name><surname>Javitt</surname><given-names>D</given-names></name></person-group>. <article-title>From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment</article-title>. <source/>Neuropsychopharmacology (<year>2012</year>) <volume>37</volume>:<fpage>4</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2011.181</pub-id><pub-id pub-id-type="pmid">21956446</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Seibyl</surname><given-names>JP</given-names></name><name><surname>Freeman</surname><given-names>GK</given-names></name><name><surname>Delaney</surname><given-names>R</given-names></name><name><surname>Bremner</surname><given-names>JD</given-names></name><etal></etal></person-group>. <article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source/>Arch Gen Psychiatry (<year>1994</year>) <volume>51</volume>:<fpage>199</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950030035004</pub-id><pub-id pub-id-type="pmid">8122957</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>AK</given-names></name><name><surname>Pinals</surname><given-names>DA</given-names></name><name><surname>Adler</surname><given-names>CM</given-names></name><name><surname>Elman</surname><given-names>I</given-names></name><name><surname>Clifton</surname><given-names>A</given-names></name><name><surname>Pickar</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics</article-title>. <source/>Neuropsychopharmacology (<year>1997</year>) <volume>17</volume>:<fpage>141</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S0893-133X(97)00036-5</pub-id><pub-id pub-id-type="pmid">9272481</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahti</surname><given-names>AC</given-names></name><name><surname>Koffel</surname><given-names>B</given-names></name><name><surname>LaPorte</surname><given-names>D</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name></person-group>. <article-title>Subanesthetic doses of ketamine stimulate psychosis in schizophrenia</article-title>. <source/>Neuropsychopharmacology (<year>1995</year>) <volume>13</volume>:<fpage>9</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/0893-133X(94)00131-I</pub-id><pub-id pub-id-type="pmid">8526975</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennox</surname><given-names>BR</given-names></name><name><surname>Palmer-Cooper</surname><given-names>EC</given-names></name><name><surname>Pollak</surname><given-names>T</given-names></name><name><surname>Hainsworth</surname><given-names>J</given-names></name><name><surname>Marks</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study</article-title>. <source/>Lancet Psychiatry (<year>2017</year>) <volume>4</volume>:<fpage>42</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(16)30375-3</pub-id><pub-id pub-id-type="pmid">27965002</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moscato</surname><given-names>EH</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>TD</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Balice-Gordon</surname><given-names>RJ</given-names></name></person-group>. <article-title>Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis</article-title>. <source/>Ann Neurol. (<year>2014</year>) <volume>76</volume>:<fpage>108</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24195</pub-id><pub-id pub-id-type="pmid">24916964</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><name><surname>Fone</surname><given-names>KC</given-names></name></person-group>. <article-title>Animal models of schizophrenia</article-title>. <source/>Br J Pharmacol. (<year>2011</year>) <volume>164</volume>:<fpage>1162</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01386.x</pub-id><pub-id pub-id-type="pmid">21449915</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>AJ</given-names></name></person-group>. <article-title>NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia</article-title>. <source/>Prog Brain Res. (<year>2009</year>) <volume>179</volume>:<fpage>51</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0079-6123(09)17906-2</pub-id><pub-id pub-id-type="pmid">20302817</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NC</given-names></name><name><surname>Bagade</surname><given-names>S</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Kavvoura</surname><given-names>FK</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database</article-title>. <source/>Nat Genet. (<year>2008</year>) <volume>40</volume>:<fpage>827</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/ng.171</pub-id><pub-id pub-id-type="pmid">18583979</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Schizophrenia Working Group of the Psychiatric</collab><name><surname>Genomics</surname><given-names>C</given-names></name></person-group>
<article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>. <source/>Nature (<year>2014</year>) <volume>511</volume>:<fpage>421</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature13595</pub-id><pub-id pub-id-type="pmid">25056061</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarabeux</surname><given-names>J</given-names></name><name><surname>Kebir</surname><given-names>O</given-names></name><name><surname>Gauthier</surname><given-names>J</given-names></name><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Xiong</surname><given-names>L</given-names></name><name><surname>Piton</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia</article-title>. <source/>Transl Psychiatry (<year>2011</year>) <volume>1</volume>:<fpage>e55</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2011.52</pub-id><pub-id pub-id-type="pmid">22833210</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boks</surname><given-names>MP</given-names></name><name><surname>Rietkerk</surname><given-names>T</given-names></name><name><surname>van de Beek</surname><given-names>MH</given-names></name><name><surname>Sommer</surname><given-names>IE</given-names></name><name><surname>de Koning</surname><given-names>TJ</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name></person-group>. <article-title>Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia</article-title>. <source/>Eur Neuropsychopharmacol. (<year>2007</year>) <volume>17</volume>:<fpage>567</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2006.12.003</pub-id><pub-id pub-id-type="pmid">17250995</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Chaudhury</surname><given-names>NH</given-names></name><name><surname>Khan</surname><given-names>UA</given-names></name><name><surname>Paniagua</surname><given-names>B</given-names></name><name><surname>Styner</surname><given-names>MA</given-names></name><name><surname>Asllani</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver</article-title>. <source/>Neuron (<year>2013</year>) <volume>78</volume>:<fpage>81</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.02.011</pub-id><pub-id pub-id-type="pmid">23583108</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homayoun</surname><given-names>H</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group>. <article-title>NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</article-title>. <source/>J Neurosci. (<year>2007</year>) <volume>27</volume>:<fpage>11496</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2213-07.2007</pub-id><pub-id pub-id-type="pmid">17959792</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maccaferri</surname><given-names>G</given-names></name><name><surname>Dingledine</surname><given-names>R</given-names></name></person-group>. <article-title>Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons</article-title>. <source/>J Neurosci. (<year>2002</year>) <volume>22</volume>:<fpage>5462</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-13-05462.2002</pub-id><pub-id pub-id-type="pmid">12097498</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poels</surname><given-names>EM</given-names></name><name><surname>Kegeles</surname><given-names>LS</given-names></name><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Slifstein</surname><given-names>M</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Imaging glutamate in schizophrenia: review of findings and implications for drug discovery</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>19</volume>:<fpage>20</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2013.136</pub-id><pub-id pub-id-type="pmid">24166406</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Lewandowski</surname><given-names>NM</given-names></name><name><surname>Corcoran</surname><given-names>CM</given-names></name><name><surname>Moore</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Malaspina</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders</article-title>. <source/>Arch Gen Psychiatry (<year>2009</year>) <volume>66</volume>:<fpage>938</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.115</pub-id><pub-id pub-id-type="pmid">19736350</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papouin</surname><given-names>T</given-names></name><name><surname>Oliet</surname><given-names>SH</given-names></name></person-group>. <article-title>Organization, control and function of extrasynaptic NMDA receptors</article-title>. <source/>Philos Trans R Soc Lond B Biol Sci. (<year>2014</year>) <volume>369</volume>:<fpage>20130601</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0601</pub-id><pub-id pub-id-type="pmid">25225095</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panatier</surname><given-names>A</given-names></name><name><surname>Theodosis</surname><given-names>DT</given-names></name><name><surname>Mothet</surname><given-names>JP</given-names></name><name><surname>Touquet</surname><given-names>B</given-names></name><name><surname>Pollegioni</surname><given-names>L</given-names></name><name><surname>Poulain</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>Glia-derived D-serine controls NMDA receptor activity and synaptic memory</article-title>. <source/>Cell (<year>2006</year>) <volume>125</volume>:<fpage>775</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.02.051</pub-id><pub-id pub-id-type="pmid">16713567</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henneberger</surname><given-names>C</given-names></name><name><surname>Papouin</surname><given-names>T</given-names></name><name><surname>Oliet</surname><given-names>SH</given-names></name><name><surname>Rusakov</surname><given-names>DA</given-names></name></person-group>. <article-title>Long-term potentiation depends on release of D-serine from astrocytes</article-title>. <source/>Nature (<year>2010</year>) <volume>463</volume>:<fpage>232</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nature08673</pub-id><pub-id pub-id-type="pmid">20075918</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Meur</surname><given-names>K</given-names></name><name><surname>Galante</surname><given-names>M</given-names></name><name><surname>Angulo</surname><given-names>MC</given-names></name><name><surname>Audinat</surname><given-names>E</given-names></name></person-group>. <article-title>Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus</article-title>. <source/>J Physiol. (<year>2007</year>) <volume>580</volume>(<issue>Pt 2</issue>):<fpage>373</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2006.123570</pub-id><pub-id pub-id-type="pmid">17185337</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>TM</given-names></name><name><surname>Scott</surname><given-names>V</given-names></name><name><surname>Naskar</surname><given-names>K</given-names></name><name><surname>Joe</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>CH</given-names></name><name><surname>Stern</surname><given-names>JE</given-names></name></person-group>. <article-title>State-dependent changes in astrocyte regulation of extrasynaptic NMDA receptor signalling in neurosecretory neurons</article-title>. <source/>J Physiol. (<year>2011</year>) <volume>589</volume>(<issue>Pt 16</issue>):<fpage>3929</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2011.207340</pub-id><pub-id pub-id-type="pmid">21690192</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Povysheva</surname><given-names>NV</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group>. <article-title>Tonic NMDA receptor-mediated current in prefrontal cortical pyramidal cells and fast-spiking interneurons</article-title>. <source/>J Neurophysiol. (<year>2012</year>) <volume>107</volume>:<fpage>2232</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1152/jn.01017.2011</pub-id><pub-id pub-id-type="pmid">22236713</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>DJ</given-names></name><name><surname>Slater</surname><given-names>NT</given-names></name></person-group>. <article-title>The developmental onset of NMDA receptor-channel activity during neuronal migration</article-title>. <source/>Neuropharmacology (<year>1993</year>) <volume>32</volume>:<fpage>1239</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/0028-3908(93)90018-X</pub-id><pub-id pub-id-type="pmid">7509049</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Biancardi</surname><given-names>VC</given-names></name><name><surname>Stern</surname><given-names>JE</given-names></name></person-group>. <article-title>An increased extrasynaptic NMDA tone inhibits A-type K(+) current and increases excitability of hypothalamic neurosecretory neurons in hypertensive rats</article-title>. <source/>J Physiol. (<year>2017</year>) <volume>595</volume>:<fpage>4647</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1113/JP274327</pub-id><pub-id pub-id-type="pmid">28378360</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellin</surname><given-names>T</given-names></name><name><surname>Pascual</surname><given-names>O</given-names></name><name><surname>Gobbo</surname><given-names>S</given-names></name><name><surname>Pozzan</surname><given-names>T</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name><name><surname>Carmignoto</surname><given-names>G</given-names></name></person-group>. <article-title>Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors</article-title>. <source/>Neuron (<year>2004</year>) <volume>43</volume>:<fpage>729</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2004.08.011</pub-id><pub-id pub-id-type="pmid">15339653</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balu</surname><given-names>DT</given-names></name></person-group>. <article-title>The NMDA receptor and schizophrenia: from pathophysiology to treatment</article-title>. <source/>Adv Pharmacol. (<year>2016</year>) <volume>76</volume>:<fpage>351</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apha.2016.01.006</pub-id><pub-id pub-id-type="pmid">27288082</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Borgmann-Winter</surname><given-names>KE</given-names></name><name><surname>MacDonald</surname><given-names>ML</given-names></name><name><surname>Kaprielian</surname><given-names>H</given-names></name><name><surname>Stucky</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2015</year>) <volume>20</volume>:<fpage>1091</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.115</pub-id><pub-id pub-id-type="pmid">25330739</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riebe</surname><given-names>I</given-names></name><name><surname>Seth</surname><given-names>H</given-names></name><name><surname>Culley</surname><given-names>G</given-names></name><name><surname>Dosa</surname><given-names>Z</given-names></name><name><surname>Radi</surname><given-names>S</given-names></name><name><surname>Strand</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Tonically active NMDA receptors–a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum</article-title>. <source/>Eur J Neurosci. (<year>2016</year>) <volume>43</volume>:<fpage>169</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1111/ejn.13128</pub-id><pub-id pub-id-type="pmid">26547631</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertz</surname><given-names>L</given-names></name><name><surname>Rothman</surname><given-names>DL</given-names></name></person-group>. <article-title>Glucose, lactate, beta-hydroxybutyrate, acetate, GABA, and succinate as Substrates for synthesis of glutamate and GABA in the glutamine-glutamate/GABA Cycle</article-title>. <source/>Adv Neurobiol. (<year>2016</year>) <volume>13</volume>:<fpage>9</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-45096-4_2</pub-id><pub-id pub-id-type="pmid">27885625</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzingounis</surname><given-names>AV</given-names></name><name><surname>Wadiche</surname><given-names>JI</given-names></name></person-group>. <article-title>Glutamate transporters: confining runaway excitation by shaping synaptic transmission</article-title>. <source/>Nat Rev Neurosci. (<year>2007</year>) <volume>8</volume>:<fpage>935</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2274</pub-id><pub-id pub-id-type="pmid">17987031</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araque</surname><given-names>A</given-names></name><name><surname>Carmignoto</surname><given-names>G</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name><name><surname>Oliet</surname><given-names>SH</given-names></name><name><surname>Robitaille</surname><given-names>R</given-names></name><name><surname>Volterra</surname><given-names>A</given-names></name></person-group>. <article-title>Gliotransmitters travel in time and space</article-title>. <source/>Neuron (<year>2014</year>) <volume>81</volume>:<fpage>728</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.02.007</pub-id><pub-id pub-id-type="pmid">24559669</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>DH</given-names></name><name><surname>Han</surname><given-names>KS</given-names></name><name><surname>Shim</surname><given-names>JW</given-names></name><name><surname>Yoon</surname><given-names>BE</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Bae</surname><given-names>JY</given-names></name><etal></etal></person-group>. <article-title>TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation</article-title>. <source/>Cell (<year>2012</year>) <volume>151</volume>:<fpage>25</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.09.005</pub-id><pub-id pub-id-type="pmid">23021213</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verleysdonk</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>H</given-names></name><name><surname>Willker</surname><given-names>W</given-names></name><name><surname>Leibfritz</surname><given-names>D</given-names></name><name><surname>Hamprecht</surname><given-names>B</given-names></name></person-group>. <article-title>Rapid uptake and degradation of glycine by astroglial cells in culture: synthesis and release of serine and lactate</article-title>. <source/>Glia (<year>1999</year>) <volume>27</volume>:<fpage>239</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="pmid">10457370</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saransaari</surname><given-names>P</given-names></name><name><surname>Oja</surname><given-names>SS</given-names></name></person-group>. <article-title>Characteristics of hippocampal glycine release in cell-damaging conditions in the adult and developing mouse</article-title>. <source/>Neurochem Res. (<year>2001</year>) <volume>26</volume>:<fpage>845</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1023/A:1011624421505</pub-id><pub-id pub-id-type="pmid">11565618</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>K</given-names></name><name><surname>Hosoi</surname><given-names>N</given-names></name><name><surname>Kaneko</surname><given-names>R</given-names></name><name><surname>Tominaga</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name></person-group>. <article-title>Glycine release from astrocytes via functional reversal of GlyT1</article-title>. <source/>J Neurochem. (<year>2017</year>) <volume>140</volume>:<fpage>395</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13741</pub-id><pub-id pub-id-type="pmid">27419919</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>HC</given-names></name><name><surname>Chou</surname><given-names>YC</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name></person-group>. <article-title>P2X7 R-mediated Ca(2+) -independent d-serine release via pannexin-1 of the P2X7 R-pannexin-1 complex in astrocytes</article-title>. <source/>Glia (<year>2015</year>) <volume>63</volume>:<fpage>877</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22790</pub-id><pub-id pub-id-type="pmid">25630251</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolosker</surname><given-names>H</given-names></name><name><surname>Balu</surname><given-names>DT</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group>. <article-title>The rise and fall of the d-serine-mediated gliotransmission hypothesis</article-title>. <source/>Trends Neurosci. (<year>2016</year>) <volume>39</volume>:<fpage>712</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2016.09.007</pub-id><pub-id pub-id-type="pmid">27742076</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Moderate UV exposure enhances learning and memory by promoting a novel glutamate biosynthetic pathway in the brain</article-title>. <source/>Cell (<year>2018</year>) <volume>173</volume>:<fpage>1716</fpage>–<lpage>27e17</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.04.014</pub-id><pub-id pub-id-type="pmid">29779945</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uwechue</surname><given-names>NM</given-names></name><name><surname>Marx</surname><given-names>MC</given-names></name><name><surname>Chevy</surname><given-names>Q</given-names></name><name><surname>Billups</surname><given-names>B</given-names></name></person-group>. <article-title>Activation of glutamate transport evokes rapid glutamine release from perisynaptic astrocytes</article-title>. <source/>J Physiol. (<year>2012</year>) <volume>590</volume>:<fpage>2317</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2011.226605</pub-id><pub-id pub-id-type="pmid">22411007</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>A</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>LJ</given-names></name></person-group>. <article-title>Glutamate transporter protein subtypes are expressed differentially during rat CNS development</article-title>. <source/>J Neurosci. (<year>1997</year>) <volume>17</volume>:<fpage>8363</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-21-08363.1997</pub-id><pub-id pub-id-type="pmid">9334410</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugeto</surname><given-names>O</given-names></name><name><surname>Ullensvang</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>LM</given-names></name><name><surname>Chaudhry</surname><given-names>FA</given-names></name><name><surname>Honore</surname><given-names>T</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Brain glutamate transporter proteins form homomultimers</article-title>. <source/>J Biol Chem. (<year>1996</year>) <volume>271</volume>:<fpage>27715</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.44.27715</pub-id><pub-id pub-id-type="pmid">8910364</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>MacDonald</surname><given-names>ML</given-names></name><name><surname>Elswick</surname><given-names>DE</given-names></name><name><surname>Sweet</surname><given-names>RA</given-names></name></person-group>. <article-title>The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies</article-title>. <source/>Ann N Y Acad Sci. (<year>2015</year>) <volume>1338</volume>:<fpage>38</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.12547</pub-id><pub-id pub-id-type="pmid">25315318</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullumsmith</surname><given-names>RE</given-names></name><name><surname>O'Donovan</surname><given-names>SM</given-names></name><name><surname>Drummond</surname><given-names>JB</given-names></name><name><surname>Benesh</surname><given-names>FS</given-names></name><name><surname>Simmons</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?</article-title>
<source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>:<fpage>823</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.148</pub-id><pub-id pub-id-type="pmid">26416546</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donovan</surname><given-names>SM</given-names></name><name><surname>Hasselfeld</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>D</given-names></name><name><surname>Simmons</surname><given-names>M</given-names></name><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia</article-title>. <source/>Transl Psychiatry (<year>2015</year>) <volume>5</volume>:<fpage>e579</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2015.74</pub-id><pub-id pub-id-type="pmid">26057049</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>A</given-names></name><name><surname>Asan</surname><given-names>E</given-names></name><name><surname>Lesch</surname><given-names>KP</given-names></name><name><surname>Kugler</surname><given-names>P</given-names></name></person-group>. <article-title>A splice variant of glutamate transporter GLT1/EAAT2 expressed in neurons: cloning and localization in rat nervous system</article-title>. <source/>Neuroscience (<year>2002</year>) <volume>109</volume>:<fpage>45</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(01)00451-1</pub-id><pub-id pub-id-type="pmid">11784699</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Gonzalez</surname><given-names>IM</given-names></name><name><surname>Garcia-Tardon</surname><given-names>N</given-names></name><name><surname>Cubelos</surname><given-names>B</given-names></name><name><surname>Gimenez</surname><given-names>C</given-names></name><name><surname>Zafra</surname><given-names>F</given-names></name></person-group>. <article-title>The glutamate transporter GLT1b interacts with the scaffold protein PSD-95</article-title>. <source/>J Neurochem. (<year>2008</year>) <volume>105</volume>:<fpage>1834</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05281.x</pub-id><pub-id pub-id-type="pmid">18248606</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underhill</surname><given-names>SM</given-names></name><name><surname>Wheeler</surname><given-names>DS</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group>. <article-title>Differential regulation of two isoforms of the glial glutamate transporter EAAT2 by DLG1 and CaMKII</article-title>. <source/>J Neurosci. (<year>2015</year>) <volume>35</volume>:<fpage>5260</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4365-14.2015</pub-id><pub-id pub-id-type="pmid">25834051</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>RM</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Heilig</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name></person-group>. <article-title>Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>64</volume>:<fpage>810</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.001</pub-id><pub-id pub-id-type="pmid">18550032</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>RM</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Saksida</surname><given-names>LM</given-names></name><name><surname>Bussey</surname><given-names>TJ</given-names></name><name><surname>Heilig</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name></person-group>. <article-title>Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia</article-title>. <source/>Neuropsychopharmacology (<year>2009</year>) <volume>34</volume>:<fpage>1578</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2008.215</pub-id><pub-id pub-id-type="pmid">19078949</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Watase</surname><given-names>K</given-names></name><name><surname>Manabe</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1</article-title>. <source/>Science (<year>1997</year>) <volume>276</volume>:<fpage>1699</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1126/science.276.5319.1699</pub-id><pub-id pub-id-type="pmid">9180080</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiryk</surname><given-names>A</given-names></name><name><surname>Aida</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Wilczynski</surname><given-names>GM</given-names></name><name><surname>Meyza</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction</article-title>. <source/>Neurotox Res. (<year>2008</year>) <volume>13</volume>:<fpage>19</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/BF03033364</pub-id><pub-id pub-id-type="pmid">18367437</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsugami</surname><given-names>TR</given-names></name><name><surname>Tanemura</surname><given-names>K</given-names></name><name><surname>Mieda</surname><given-names>M</given-names></name><name><surname>Nakatomi</surname><given-names>R</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>From the cover: indispensability of the glutamate transporters GLAST and GLT1 to brain development</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2006</year>) <volume>103</volume>:<fpage>12161</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0509144103</pub-id><pub-id pub-id-type="pmid">16880397</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aida</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>J</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Tanimura</surname><given-names>A</given-names></name><name><surname>Iino</surname><given-names>Y</given-names></name><name><surname>Soma</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice</article-title>. <source/>Neuropsychopharmacology (<year>2015</year>) <volume>40</volume>:<fpage>1569</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.26</pub-id><pub-id pub-id-type="pmid">25662838</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnth-Jensen</surname><given-names>N</given-names></name><name><surname>Jabaudon</surname><given-names>D</given-names></name><name><surname>Scanziani</surname><given-names>M</given-names></name></person-group>. <article-title>Cooperation between independent hippocampal synapses is controlled by glutamate uptake</article-title>. <source/>Nat Neurosci. (<year>2002</year>) <volume>5</volume>:<fpage>325</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/nn825</pub-id><pub-id pub-id-type="pmid">11896395</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairman</surname><given-names>WA</given-names></name><name><surname>Vandenberg</surname><given-names>RJ</given-names></name><name><surname>Arriza</surname><given-names>JL</given-names></name><name><surname>Kavanaugh</surname><given-names>MP</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group>. <article-title>An excitatory amino-acid transporter with properties of a ligand-gated chloride channel</article-title>. <source/>Nature (<year>1995</year>) <volume>375</volume>:<fpage>599</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1038/375599a0</pub-id><pub-id pub-id-type="pmid">7791878</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadiche</surname><given-names>JI</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name><name><surname>Kavanaugh</surname><given-names>MP</given-names></name></person-group>. <article-title>Ion fluxes associated with excitatory amino acid transport</article-title>. <source/>Neuron (<year>1995</year>) <volume>15</volume>:<fpage>721</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0896-6273(95)90159-0</pub-id><pub-id pub-id-type="pmid">7546750</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veruki</surname><given-names>ML</given-names></name><name><surname>Morkve</surname><given-names>SH</given-names></name><name><surname>Hartveit</surname><given-names>E</given-names></name></person-group>. <article-title>Activation of a presynaptic glutamate transporter regulates synaptic transmission through electrical signaling</article-title>. <source/>Nat Neurosci. (<year>2006</year>) <volume>9</volume>:<fpage>1388</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/nn1793</pub-id><pub-id pub-id-type="pmid">17041592</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niklaus</surname><given-names>S</given-names></name><name><surname>Cadetti</surname><given-names>L</given-names></name><name><surname>Vom</surname><given-names>Berg-Maurer CM</given-names></name><name><surname>Lehnherr</surname><given-names>A</given-names></name><name><surname>Hotz</surname><given-names>AL</given-names></name><name><surname>Forster</surname><given-names>IC</given-names></name><etal></etal></person-group>. <article-title>Shaping of signal transmission at the photoreceptor synapse by EAAT2 glutamate transporters</article-title>. <source/>eNeuro (<year>2017</year>) <volume>4</volume>:<fpage>ENEURO.0339</fpage>–<lpage>16.2017</lpage>. <pub-id pub-id-type="doi">10.1523/ENEURO.0339-16.2017</pub-id><pub-id pub-id-type="pmid">28612046</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jelen</surname><given-names>LA</given-names></name><name><surname>King</surname><given-names>S</given-names></name><name><surname>Mullins</surname><given-names>PG</given-names></name><name><surname>Stone</surname><given-names>JM</given-names></name></person-group>. <article-title>Beyond static measures: a review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia</article-title>. <source/>J Psychopharmacol. (<year>2018</year>) <volume>32</volume>:<fpage>497</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1177/0269881117747579</pub-id><pub-id pub-id-type="pmid">29368979</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>K</given-names></name><name><surname>Egerton</surname><given-names>A</given-names></name><name><surname>Kempton</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>McGuire</surname><given-names>PK</given-names></name></person-group>. <article-title>Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies</article-title>. <source/>JAMA Psychiatry (<year>2016</year>) <volume>73</volume>:<fpage>665</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.0442</pub-id><pub-id pub-id-type="pmid">27304221</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraguljac</surname><given-names>NV</given-names></name><name><surname>Frolich</surname><given-names>MA</given-names></name><name><surname>Tran</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>DM</given-names></name><name><surname>Nichols</surname><given-names>N</given-names></name><name><surname>Barton-McArdle</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers</article-title>. <source/>Mol Psychiatry (<year>2017</year>) <volume>22</volume>:<fpage>562</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.122</pub-id><pub-id pub-id-type="pmid">27480494</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><name><surname>Lindstrom</surname><given-names>LH</given-names></name><name><surname>Iyo</surname><given-names>M</given-names></name></person-group>. <article-title>Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients</article-title>. <source/>BMC Psychiatry (<year>2005</year>) <volume>5</volume>:<fpage>6</fpage>. <pub-id pub-id-type="doi">10.1186/1471-244X-5-6</pub-id><pub-id pub-id-type="pmid">15683541</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustillo</surname><given-names>JR</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>T</given-names></name><name><surname>Lemke</surname><given-names>N</given-names></name><name><surname>Abbott</surname><given-names>C</given-names></name><name><surname>Qualls</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T</article-title>. <source/>JAMA Psychiatry (<year>2014</year>) <volume>71</volume>:<fpage>265</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.3939</pub-id><pub-id pub-id-type="pmid">24402128</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>K</given-names></name><name><surname>Norman</surname><given-names>R</given-names></name><name><surname>Theberge</surname><given-names>J</given-names></name><name><surname>Densmore</surname><given-names>M</given-names></name><name><surname>Schaefer</surname><given-names>B</given-names></name><name><surname>Williamson</surname><given-names>P</given-names></name></person-group>. <article-title>Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia</article-title>. <source/>Psychiatry Res. (<year>2015</year>) <volume>233</volume>:<fpage>180</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.pscychresns.2015.06.003</pub-id><pub-id pub-id-type="pmid">26163385</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavus</surname><given-names>I</given-names></name><name><surname>Kasoff</surname><given-names>WS</given-names></name><name><surname>Cassaday</surname><given-names>MP</given-names></name><name><surname>Jacob</surname><given-names>R</given-names></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><etal></etal></person-group>. <article-title>Extracellular metabolites in the cortex and hippocampus of epileptic patients</article-title>. <source/>Ann Neurol. (<year>2005</year>) <volume>57</volume>:<fpage>226</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20380</pub-id><pub-id pub-id-type="pmid">15668975</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>MJ</given-names></name><name><surname>Spencer</surname><given-names>DD</given-names></name><name><surname>Runden-Pran</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>JC</given-names></name><name><surname>Malthankar</surname><given-names>GV</given-names></name><etal></etal></person-group>. <article-title>Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy</article-title>. <source/>Lancet (<year>2004</year>) <volume>363</volume>:<fpage>28</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)15166-5</pub-id><pub-id pub-id-type="pmid">14723991</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>SL</given-names></name><name><surname>Carlson</surname><given-names>GC</given-names></name><name><surname>Coulter</surname><given-names>DA</given-names></name></person-group>. <article-title>Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1</article-title>. <source/>J Neurosci. (<year>2006</year>) <volume>26</volume>:<fpage>8537</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0329-06.2006</pub-id><pub-id pub-id-type="pmid">16914680</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortinski</surname><given-names>PI</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Mungenast</surname><given-names>A</given-names></name><name><surname>Yue</surname><given-names>C</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><etal></etal></person-group>. <article-title>Selective induction of astrocytic gliosis generates deficits in neuronal inhibition</article-title>. <source/>Nat Neurosci. (<year>2010</year>) <volume>13</volume>:<fpage>584</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2535</pub-id><pub-id pub-id-type="pmid">20418874</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>T</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Beckstrom</surname><given-names>H</given-names></name><name><surname>Zaveri</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>TS</given-names></name><etal></etal></person-group>. <article-title>Recurrent seizures and brain pathology after inhibition of glutamine synthetase in the hippocampus in rats</article-title>. <source/>Brain (<year>2008</year>) <volume>131</volume>(<issue>Pt 8</issue>):<fpage>2061</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awn133</pub-id><pub-id pub-id-type="pmid">18669513</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Dao</surname><given-names>DN</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Shekhtman</surname><given-names>G</given-names></name><name><surname>Quick</surname><given-names>KL</given-names></name><etal></etal></person-group>. <article-title>Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase</article-title>. <source/>Science (<year>2007</year>) <volume>318</volume>:<fpage>1645</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1148045</pub-id><pub-id pub-id-type="pmid">18063801</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Curley</surname><given-names>AA</given-names></name><name><surname>Glausier</surname><given-names>JR</given-names></name><name><surname>Volk</surname><given-names>DW</given-names></name></person-group>. <article-title>Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia</article-title>. <source/>Trends Neurosci. (<year>2012</year>) <volume>35</volume>:<fpage>57</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2011.10.004</pub-id><pub-id pub-id-type="pmid">22154068</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steullet</surname><given-names>P</given-names></name><name><surname>Cabungcal</surname><given-names>JH</given-names></name><name><surname>Coyle</surname><given-names>J</given-names></name><name><surname>Didriksen</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>K</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name><etal></etal></person-group>. <article-title>Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2017</year>) <volume>22</volume>:<fpage>936</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2017.47</pub-id><pub-id pub-id-type="pmid">28322275</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodge</surname><given-names>DJ</given-names></name><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group>. <article-title>A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia</article-title>. <source/>J Neurosci. (<year>2009</year>) <volume>29</volume>:<fpage>2344</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5419-08.2009</pub-id><pub-id pub-id-type="pmid">19244511</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasella</surname><given-names>E</given-names></name><name><surname>Bechelli</surname><given-names>L</given-names></name><name><surname>Ogando</surname><given-names>MB</given-names></name><name><surname>Mininni</surname><given-names>C</given-names></name><name><surname>Di Guilmi</surname><given-names>MN</given-names></name><name><surname>De Fino</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2018</year>) <volume>115</volume>:<fpage>3476</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1719897115</pub-id><pub-id pub-id-type="pmid">29531031</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Pino</surname><given-names>I</given-names></name><name><surname>Garcia-Frigola</surname><given-names>C</given-names></name><name><surname>Dehorter</surname><given-names>N</given-names></name><name><surname>Brotons-Mas</surname><given-names>JR</given-names></name><name><surname>Alvarez-Salvado</surname><given-names>E</given-names></name><name><surname>Martinez de Lagran</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes</article-title>. <source/>Neuron (<year>2013</year>) <volume>79</volume>:<fpage>1152</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.07.010</pub-id><pub-id pub-id-type="pmid">24050403</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondziella</surname><given-names>D</given-names></name><name><surname>Brenner</surname><given-names>E</given-names></name><name><surname>Eyjolfsson</surname><given-names>EM</given-names></name><name><surname>Markinhuhta</surname><given-names>KR</given-names></name><name><surname>Carlsson</surname><given-names>ML</given-names></name><name><surname>Sonnewald</surname><given-names>U</given-names></name></person-group>. <article-title>Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure</article-title>. <source/>Neuropsychopharmacology (<year>2006</year>) <volume>31</volume>:<fpage>1880</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300993</pub-id><pub-id pub-id-type="pmid">16395297</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>V</given-names></name><name><surname>Wong</surname><given-names>AH</given-names></name><name><surname>Roder</surname><given-names>JC</given-names></name></person-group>. <article-title>Contributions of the D-serine pathway to schizophrenia</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>:<fpage>1484</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.030</pub-id><pub-id pub-id-type="pmid">21295046</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Komatsu</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Shinoda</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia</article-title>. <source/>Arch Gen Psychiatry (<year>2003</year>) <volume>60</volume>:<fpage>572</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.60.6.572</pub-id><pub-id pub-id-type="pmid">12796220</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendikov</surname><given-names>I</given-names></name><name><surname>Nadri</surname><given-names>C</given-names></name><name><surname>Amar</surname><given-names>S</given-names></name><name><surname>Panizzutti</surname><given-names>R</given-names></name><name><surname>De Miranda</surname><given-names>J</given-names></name><name><surname>Wolosker</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia</article-title>. <source/>Schizophr Res. (<year>2007</year>) <volume>90</volume>:<fpage>41</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2006.10.010</pub-id><pub-id pub-id-type="pmid">17156977</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Ujike</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Otani</surname><given-names>K</given-names></name><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Morio</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>A genetic variant of the serine racemase gene is associated with schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2007</year>) <volume>61</volume>:<fpage>1200</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2006.07.025</pub-id><pub-id pub-id-type="pmid">17067558</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>V</given-names></name><name><surname>Roder</surname><given-names>JC</given-names></name></person-group>. <article-title>The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia</article-title>. <source/>Neurosci Biobehav Rev. (<year>2010</year>) <volume>34</volume>:<fpage>351</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2009.08.002</pub-id><pub-id pub-id-type="pmid">19695284</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Green</surname><given-names>MF</given-names></name><name><surname>Hellemann</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>PW</given-names></name><etal></etal></person-group>. <article-title>Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor</article-title>. <source/>JAMA Psychiatry (<year>2013</year>) <volume>70</volume>:<fpage>1267</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.2159</pub-id><pub-id pub-id-type="pmid">24089054</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>PW</given-names></name><name><surname>Yang</surname><given-names>HT</given-names></name><etal></etal></person-group>. <article-title>Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial</article-title>. <source/>Biol Psychiatry (<year>2017</year>) <volume>84</volume>:<fpage>422</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2017.12.006</pub-id><pub-id pub-id-type="pmid">29397899</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St Clair</surname><given-names>D</given-names></name><name><surname>Blackwood</surname><given-names>D</given-names></name><name><surname>Muir</surname><given-names>W</given-names></name><name><surname>Carothers</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Spowart</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Association within a family of a balanced autosomal translocation with major mental illness</article-title>. <source/>Lancet (<year>1990</year>) <volume>336</volume>:<fpage>13</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(90)91520-K</pub-id><pub-id pub-id-type="pmid">1973210</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>JK</given-names></name><name><surname>Wilson-Annan</surname><given-names>JC</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Christie</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>MS</given-names></name><name><surname>Semple</surname><given-names>CA</given-names></name><etal></etal></person-group>. <article-title>Disruption of two novel genes by a translocation co-segregating with schizophrenia</article-title>. <source/>Hum Mol Genet. (<year>2000</year>) <volume>9</volume>:<fpage>1415</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/9.9.1415</pub-id><pub-id pub-id-type="pmid">10814723</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Keilhoff</surname><given-names>G</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name></person-group>
<article-title>Reduced density of DISC1 expressing astrocytes in the dentate gyrus but not in the subventricular zone in schizophrenia</article-title>. <source/>Neuropsychopharmacology (<year>2018</year>) <volume>43</volume>:<fpage>457</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.242</pub-id><pub-id pub-id-type="pmid">29326433</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>TM</given-names></name><name><surname>Abazyan</surname><given-names>S</given-names></name><name><surname>Abazyan</surname><given-names>B</given-names></name><name><surname>Nomura</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion</article-title>. <source/>Mol Psychiatry (<year>2013</year>) <volume>18</volume>:<fpage>557</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.97</pub-id><pub-id pub-id-type="pmid">22801410</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Shevelkin</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Pletnikov</surname><given-names>M</given-names></name></person-group>. <article-title>DISC1, astrocytes and neuronal maturation: a possible mechanistic link with implications for mental disorders</article-title>. <source/>J Neurochem. (<year>2016</year>) <volume>138</volume>:<fpage>518</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13663</pub-id><pub-id pub-id-type="pmid">27187935</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terrillion</surname><given-names>CE</given-names></name><name><surname>Abazyan</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>Shevelkin</surname><given-names>AV</given-names></name><name><surname>Jouroukhin</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>DISC1 in astrocytes influences adult neurogenesis and hippocampus-dependent behaviors in mice</article-title>. <source/>Neuropsychopharmacology (<year>2017</year>) <volume>42</volume>:<fpage>2242</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.129</pub-id><pub-id pub-id-type="pmid">28631721</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JW</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name></person-group>. <article-title>Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia</article-title>. <source/>Biochem Pharmacol. (<year>2013</year>) <volume>86</volume>:<fpage>1122</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2013.06.031</pub-id><pub-id pub-id-type="pmid">23856289</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>AM</given-names></name><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>DC</given-names></name><name><surname>Milner</surname><given-names>TA</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Acetylcholine alpha7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex</article-title>. <source/>Synapse (<year>2011</year>) <volume>65</volume>:<fpage>1350</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20977</pub-id><pub-id pub-id-type="pmid">21858872</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gahring</surname><given-names>LC</given-names></name><name><surname>Persiyanov</surname><given-names>K</given-names></name><name><surname>Dunn</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>EL</given-names></name><name><surname>Rogers</surname><given-names>SW</given-names></name></person-group>. <article-title>Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus</article-title>. <source/>J Comp Neurol. (<year>2004</year>) <volume>468</volume>:<fpage>334</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1002/cne.10943</pub-id><pub-id pub-id-type="pmid">14681929</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JX</given-names></name><name><surname>Yakel</surname><given-names>JL</given-names></name></person-group>. <article-title>Functional alpha7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices</article-title>. <source/>J Mol Neurosci. (<year>2012</year>) <volume>48</volume>:<fpage>14</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-012-9719-3</pub-id><pub-id pub-id-type="pmid">22351110</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Vijayaraghavan</surname><given-names>S</given-names></name></person-group>. <article-title>Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2001</year>) <volume>98</volume>:<fpage>4148</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.071540198</pub-id><pub-id pub-id-type="pmid">11259680</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>FC</given-names></name><name><surname>Baumann</surname><given-names>BH</given-names></name><name><surname>Coulter</surname><given-names>DA</given-names></name><name><surname>Lynch</surname><given-names>DR</given-names></name></person-group>. <article-title>Cortical synaptic NMDA receptor deficits in alpha7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases</article-title>. <source/>Neurobiol Dis. (<year>2014</year>) <volume>63</volume>:<fpage>129</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2013.11.021</pub-id><pub-id pub-id-type="pmid">24326163</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NS</given-names></name><name><surname>Paul</surname><given-names>RK</given-names></name><name><surname>Ramamoorthy</surname><given-names>A</given-names></name><name><surname>Torjman</surname><given-names>MC</given-names></name><name><surname>Moaddel</surname><given-names>R</given-names></name><name><surname>Bernier</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells</article-title>. <source/>Cell Signal. (<year>2013</year>) <volume>25</volume>:<fpage>2634</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2013.08.025</pub-id><pub-id pub-id-type="pmid">24012499</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papouin</surname><given-names>T</given-names></name><name><surname>Dunphy</surname><given-names>JM</given-names></name><name><surname>Tolman</surname><given-names>M</given-names></name><name><surname>Dineley</surname><given-names>KT</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name></person-group>. <article-title>Septal cholinergic neuromodulation tunes the astrocyte-dependent gating of hippocampal NMDA receptors to wakefulness</article-title>. <source/>Neuron (<year>2017</year>) <volume>94</volume>:<fpage>840</fpage>–<lpage>54.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2017.04.021</pub-id><pub-id pub-id-type="pmid">28479102</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozzi</surname><given-names>A</given-names></name><name><surname>Large</surname><given-names>CH</given-names></name><name><surname>Schwarz</surname><given-names>A</given-names></name><name><surname>Bertani</surname><given-names>S</given-names></name><name><surname>Crestan</surname><given-names>V</given-names></name><name><surname>Bifone</surname><given-names>A</given-names></name></person-group>. <article-title>Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine</article-title>. <source/>Neuropsychopharmacology (<year>2008</year>) <volume>33</volume>:<fpage>1690</fpage>–<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301547</pub-id><pub-id pub-id-type="pmid">17805312</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poels</surname><given-names>EM</given-names></name><name><surname>Kegeles</surname><given-names>LS</given-names></name><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings</article-title>. <source/>Schizophr Res. (<year>2014</year>) <volume>152</volume>:<fpage>325</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2013.12.013</pub-id><pub-id pub-id-type="pmid">24418122</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragland</surname><given-names>JD</given-names></name><name><surname>Ranganath</surname><given-names>C</given-names></name><name><surname>Harms</surname><given-names>MP</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Gold</surname><given-names>JM</given-names></name><name><surname>Layher</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and item-specific encoding task</article-title>. <source/>JAMA Psychiatry (<year>2015</year>) <volume>72</volume>:<fpage>909</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.0276</pub-id><pub-id pub-id-type="pmid">26200928</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragland</surname><given-names>JD</given-names></name><name><surname>Ranganath</surname><given-names>C</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Gold</surname><given-names>JM</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>MacDonald</surname><given-names>AW</given-names><suffix>III</suffix></name><etal></etal></person-group>. <article-title>Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics</article-title>. <source/>Schizophr Bull. (<year>2012</year>) <volume>38</volume>:<fpage>114</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbr146</pub-id><pub-id pub-id-type="pmid">22124089</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragland</surname><given-names>JD</given-names></name><name><surname>Blumenfeld</surname><given-names>RS</given-names></name><name><surname>Ramsay</surname><given-names>IS</given-names></name><name><surname>Yonelinas</surname><given-names>A</given-names></name><name><surname>Yoon</surname><given-names>J</given-names></name><name><surname>Solomon</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia</article-title>. <source/>Neuroimage (<year>2012</year>) <volume>59</volume>:<fpage>1719</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.08.055</pub-id><pub-id pub-id-type="pmid">21907293</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnema</surname><given-names>SJ</given-names></name><name><surname>Scheinin</surname><given-names>M</given-names></name><name><surname>Shahid</surname><given-names>M</given-names></name><name><surname>Lehto</surname><given-names>J</given-names></name><name><surname>Borroni</surname><given-names>E</given-names></name><name><surname>Bang-Andersen</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Application of cross-species PET imaging to assess neurotransmitter release in brain</article-title>. <source/>Psychopharmacology (<year>2015</year>) <volume>232</volume>:<fpage>4129</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-015-3938-6</pub-id><pub-id pub-id-type="pmid">25921033</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>H</given-names></name></person-group>. <article-title>Cognitive function and monoamine neurotransmission in schizophrenia: evidence from positron emission tomography studies</article-title>. <source/>Front Psychiatry (<year>2018</year>) <volume>9</volume>:<fpage>228</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00228</pub-id><pub-id pub-id-type="pmid">29896132</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasic</surname><given-names>N</given-names></name><name><surname>Connemann</surname><given-names>BJ</given-names></name><name><surname>Wolf</surname><given-names>RC</given-names></name><name><surname>Tumani</surname><given-names>H</given-names></name><name><surname>Brettschneider</surname><given-names>J</given-names></name></person-group>. <article-title>Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?</article-title>
<source/>Eur Arch Psychiatry Clin Neurosci. (<year>2012</year>) <volume>262</volume>:<fpage>375</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-011-0280-9</pub-id><pub-id pub-id-type="pmid">22173848</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>HT</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Tun</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>19</volume>:<fpage>636</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2013.80</pub-id><pub-id pub-id-type="pmid">23857119</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trepanier</surname><given-names>MO</given-names></name><name><surname>Hopperton</surname><given-names>KE</given-names></name><name><surname>Mizrahi</surname><given-names>R</given-names></name><name><surname>Mechawar</surname><given-names>N</given-names></name><name><surname>Bazinet</surname><given-names>RP</given-names></name></person-group>. <article-title>Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>:<fpage>1009</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.90</pub-id><pub-id pub-id-type="pmid">27271499</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Carter</surname><given-names>CS</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Girgis</surname><given-names>RR</given-names></name><name><surname>Kegeles</surname><given-names>LS</given-names></name><etal></etal></person-group>. <article-title>Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial</article-title>. <source/>JAMA Psychiatry (<year>2018</year>) <volume>75</volume>:<fpage>11</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.3572</pub-id><pub-id pub-id-type="pmid">29167877</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girgis</surname><given-names>RR</given-names></name><name><surname>Zoghbi</surname><given-names>AW</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group>. <article-title>The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review</article-title>. <source/>J Psychiatr Res. (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.jpsychires.2018.07.006.</pub-id> [Epub ahead of print]. <pub-id pub-id-type="pmid">30055853</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Woods</surname><given-names>SW</given-names></name><name><surname>Petkova</surname><given-names>E</given-names></name><name><surname>Cornblatt</surname><given-names>B</given-names></name><name><surname>Corcoran</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial</article-title>. <source/>Lancet Psychiatry (<year>2015</year>) <volume>2</volume>:<fpage>403</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(15)00098-X</pub-id><pub-id pub-id-type="pmid">26360284</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Yee</surname><given-names>BK</given-names></name></person-group>. <article-title>Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</article-title>. <source/>Nat Rev Drug Discov. (<year>2013</year>) <volume>12</volume>:<fpage>866</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3893</pub-id><pub-id pub-id-type="pmid">24172334</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fell</surname><given-names>MJ</given-names></name><name><surname>McKinzie</surname><given-names>DL</given-names></name><name><surname>Monn</surname><given-names>JA</given-names></name><name><surname>Svensson</surname><given-names>KA</given-names></name></person-group>. <article-title>Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>:<fpage>1473</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.06.007</pub-id><pub-id pub-id-type="pmid">21704048</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>